The DOI matches its Crossref record; 109 of the 109 references it cites were found in a registry or an index.
The Akt/PKB pathway: molecular target for cancer drug discovery
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
AKT2 Inhibition of Cisplatin-induced JNK/p38 and Bax Activation by Phosphorylation of ASK1
Yuan, Z.-Q., Feldman, R. I., Sussman, G. E., Coppola, D., Nicosia, S. V., & Cheng, J. Q. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302674200 · Cited by 203
Self-citationRetractedSun, M., Yang, L., Feldman, R. I., Sun, X.-M., Bhalla, K. N., Jove, R., Nicosia, S. V., & Cheng, J. Q. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306295200 · Cited by 171
Self-citationRetractedMandal, M., Kim, S., Younes, M. N., Jasser, S. A., El‐Naggar, A. K., Mills, G. B., & Myers, J. N. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602595 · Cited by 88
RetractedPhosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Cellular survival: a play in three Akts
Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216
Vlahos, C. J., Matter, W. F., Hui, K. Y., & Brown, R. F. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37680-9 · Cited by 3,240
Mechanism of activation of protein kinase B by insulin and IGF-1.
Alessi, D. R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P., & Hemmings, B. A. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb01045.x · Cited by 3,004
Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., & Cohen, P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00122-9 · Cited by 2,826
Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K. A., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., et al. (1997) · Nature Genetics · doi:10.1038/ng0497-356 · Cited by 2,741
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551
Autophagy in Health and Disease: A Double-Edged Sword
Shintani, T., & Klionsky, D. J. (2004) · Science · doi:10.1126/science.1099993 · Cited by 2,534
Phage antibodies: filamentous phage displaying antibody variable domains
McCafferty, J., Griffiths, A. D., Winter, G., & Chiswell, D. J. (1990) · Nature · doi:10.1038/348552a0 · Cited by 2,423
Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction
Burgering, B. M. T., & Coffer, P. J. (1995) · Nature · doi:10.1038/376599a0 · Cited by 2,089
Franke, T. F., Yang, S.-I., Chan, T. O., Datta, K., Kazlauskas, A., Morrison, D. K., Kaplan, D. R., & Tsichlis, P. N. (1995) · Cell · doi:10.1016/0092-8674(95)90534-0 · Cited by 2,006
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · cited 2×
“…shown that overexpression and/or activation of Akt render tumor cells resistant to chemotherapeutic drugs and signal molecule inhibitors such as Gleevec, Iressa, Herceptin and retinoid acid (Cheng et al., 2002; Arlt et al., 2003; Knuefermann et al., 2003; Yuan et al., 2003; Nagata et al., 2004).”
BackgroundCho, H., Mu, J., Kim, J. K., Thorvaldsen, J. L., Chu, Q., Crenshaw, E. B., Kaestner, K. H., Bartolomei, M. S., Shulman, G. I., & Birnbaum, M. J. (2001) · Science · doi:10.1126/science.292.5522.1728 · Cited by 1,836
Perturbations of the AKT signaling pathway in human cancer
Altomare, D. A., & Testa, J. R. (2005) · Oncogene · doi:10.1038/sj.onc.1209085 · Cited by 1,329
Arcaro, A., & Wymann, M. P. (1993) · Biochemical Journal · doi:10.1042/bj2960297 · Cited by 1,140
Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., Manola, J., Brugarolas, J., McDonnell, T. J., Golub, T. R., et al. (2004) · Nature Medicine · doi:10.1038/nm1052 · Cited by 964
Cho, H., Thorvaldsen, J. L., Chu, Q., Feng, F., & Birnbaum, M. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100462200 · Cited by 959
AKT plays a central role in tumorigenesis
Testa, J. R., & Bellacosa, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211430998 · Cited by 944 · cited 4×
“To date, three Akt family members have been identified in mammals, designated Akt1/PKBa, Akt2/ PKBb and Akt3/PKBg (Testa and Bellacosa, 2001).”
BackgroundInfluentialA Retroviral Oncogene, akt , Encoding a Serine-Threonine Kinase Containing an SH2-Like Region
Bellacosa, A., Testa, J. R., Staal, S. P., & Tsichlis, P. N. (1991) · Science · doi:10.1126/science.1833819 · Cited by 939
Growth retardation and increased apoptosis in mice with homozygous disruption of the akt1 gene
Chen, W. S., Xu, P.-Z., Gottlob, K., Chen, M.-L., Sokol, K., Shiyanova, T., Roninson, I., Weng, W., Suzuki, R., Tobe, K., et al. (2001) · Genes & Development · doi:10.1101/gad.913901 · Cited by 928
Molecular alterations of the AKT 2 oncogene in ovarian and breast carcinomas
Bellacosa, A., De Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640412 · Cited by 837
Self-citationPDK1, the master regulator of AGC kinase signal transduction
Mora, A., Komander, D., van Aalten, D. M. F., & Alessi, D. R. (2004) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2003.12.022 · Cited by 810
Cheng, J. Q., Ruggeri, B., Klein, W. M., Sonoda, G., Altomare, D. A., Watson, D. K., & Testa, J. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3636 · Cited by 793
Self-citationStaal, S. P. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.14.5034 · Cited by 767
Chan, T. O., Rittenhouse, S. E., & Tsichlis, P. N. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.965 · Cited by 737
Cheng, J. Q., Godwin, A. K., Bellacosa, A., Taguchi, T., Franke, T. F., Hamilton, T. C., Tsichlis, P. N., & Testa, J. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.19.9267 · Cited by 736
Self-citationWymann, M. P., Bulgarelli-Leva, G., Zvelebil, M. J., Pirola, L., Vanhaesebroeck, B., Waterfield, M. D., & Panayotou, G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.4.1722 · Cited by 682
A Family with Severe Insulin Resistance and Diabetes Due to a Mutation in AKT2
George, S., Rochford, J. J., Wolfrum, C., Gray, S. L., Schinner, S., Wilson, J. C., Soos, M. A., Murgatroyd, P. R., Williams, R. M., Acerini, C. L., et al. (2004) · Science · doi:10.1126/science.1096706 · Cited by 559
Role for Akt3/Protein Kinase Bγ in Attainment of Normal Brain Size
Easton, R. M., Cho, H., Roovers, K., Shineman, D. W., Mizrahi, M., Forman, M. S., Lee, V. M.-Y., Szabolcs, M., de Jong, R., Oltersdorf, T., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.5.1869-1878.2005 · Cited by 551
Brazil, D. P., Park, J., & Hemmings, B. A. (2002) · Cell · doi:10.1016/s0092-8674(02)01083-8 · Cited by 537
Jones, P. F., Jakubowicz, T., Pitossi, F. J., Maurer, F., & Hemmings, B. A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.10.4171 · Cited by 532
Akt/Protein Kinase B Is Regulated by Autophosphorylation at the Hypothetical PDK-2 Site
Toker, A., & Newton, A. C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.8271 · Cited by 516
Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors
Lindsley, C. W., Zhao, Z., Leister, W. H., Robinson, R. G., Barnett, S. F., Defeo-Jones, D., Jones, R. E., Hartman, G. D., Huff, J. R., Huber, H. E., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.11.011 · Cited by 503
Self-citationRegulation of Protein Kinase B/Akt-Serine 473 Phosphorylation by Integrin-linked Kinase
Persad, S., Attwell, S., Gray, V., Mawji, N., Deng, J. T., Leung, D., Yan, J., Sanghera, J., Walsh, M. P., & Dedhar, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102940200 · Cited by 497
Identification of a PKB/Akt Hydrophobic Motif Ser-473 Kinase as DNA-dependent Protein Kinase
Feng, J., Park, J., Cron, P., Hess, D., & Hemmings, B. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406731200 · Cited by 488
COFFER, P. J., & WOODGETT, J. R. (1991) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1991.tb16305.x · Cited by 487
Arlt, A., Gehrz, A., Müerköster, S., Vorndamm, J., Kruse, M.-L., Fölsch, U. R., & Schäfer, H. (2003) · Oncogene · doi:10.1038/sj.onc.1206390 · Cited by 474
Sun, M., Wang, G., Paciga, J. E., Feldman, R. I., Yuan, Z.-Q., Ma, X.-L., Shelley, S. A., Jove, R., Tsichlis, P. N., Nicosia, S. V., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61714-2 · Cited by 454
Self-citationHER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells
Knuefermann, C., Lu, Y., Liu, B., Jin, W., Liang, K., Wu, L., Schmidt, M., Mills, G. B., Mendelsohn, J., & Fan, Z. (2003) · Oncogene · doi:10.1038/sj.onc.1206394 · Cited by 452
PI 3-kinase related kinases: ‘big’ players in stress-induced signaling pathways
Abraham, R. T. (2004) · DNA Repair · doi:10.1016/j.dnarep.2004.04.002 · Cited by 440
Overexpression of ErbB2 in cancer and ErbB2-targeting strategies
Yu, D., & Hung, M.-C. (2000) · Oncogene · doi:10.1038/sj.onc.1203972 · Cited by 430
Balendran, A., Casamayor, A., Deak, M., Paterson, A., Gaffney, P., Currie, R., Downes, C. P., & Alessi, D. R. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80186-9 · Cited by 429
Molecular Mechanism for the Regulation of Protein Kinase B/Akt by Hydrophobic Motif Phosphorylation
Yang, J., Cron, P., Thompson, V., Good, V. M., Hess, D., Hemmings, B. A., & Barford, D. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00550-6 · Cited by 418
Tschopp, O., Yang, Z.-Z., Brodbeck, D., Dummler, B. A., Hemmings-Mieszczak, M., Watanabe, T., Michaelis, T., Frahm, J., & Hemmings, B. A. (2005) · Development · doi:10.1242/dev.01864 · Cited by 413
Altomare, D. A., Wang, H. Q., Skele, K. L., Rienzo, A. D., Klein-Szanto, A. J., Godwin, A. K., & Testa, J. R. (2004) · Oncogene · doi:10.1038/sj.onc.1207721 · Cited by 412
BARNETT, S. F., DEFEO-JONES, D., FU, S., HANCOCK, P. J., HASKELL, K. M., JONES, R. E., KAHANA, J. A., KRAL, A. M., LEANDER, K., LEE, L. L., et al. (2005) · Biochemical Journal · doi:10.1042/bj20041140 · Cited by 396
deGraffenried, L. A., Friedrichs, W. E., Russell, D. H., Donzis, E. J., Middleton, A. K., Silva, J. M., Roth, R. A., & Hidalgo, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0035 · Cited by 387
Yuan, Z. Q., Sun, M., Feldman, R. I., Wang, G., Ma, X.-L., Jiang, C., Coppola, D., Nicosia, S. V., & Cheng, J. Q. (2000) · Oncogene · doi:10.1038/sj.onc.1203598 · Cited by 384
Self-citationPKB/Akt modulates TGF-β signalling through a direct interaction with Smad3
Remy, I., Montmarquette, A., & Michnick, S. W. (2004) · Nature Cell Biology · doi:10.1038/ncb1113 · Cited by 372
Yang, L., Dan, H. C., Sun, M., Liu, Q., Sun, X.-M., Feldman, R. I., Hamilton, A. D., Polokoff, M., Nicosia, S. V., Herlyn, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0343 · Cited by 371
Self-citationEssential Role of Phosphoinositide 3-Kinase δ in Neutrophil Directional Movement
Sadhu, C., Masinovsky, B., Dick, K., Sowell, C. G., & Staunton, D. E. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.5.2647 · Cited by 365
The Protooncogene TCL1 Is an Akt Kinase Coactivator
Laine, J., Künstle, G., Obata, T., Sha, M., & Noguchi, M. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00039-3 · Cited by 327
Tcl1 enhances Akt kinase activity and mediates its nuclear translocation
Pekarsky, Y., Koval, A., Hallas, C., Bichi, R., Tresini, M., Malstrom, S., Russo, G., Tsichlis, P., & Croce, C. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3028 · Cited by 310
Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer
Chan, S. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602162 · Cited by 301
Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions
Balsara, B. R. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh226 · Cited by 295
Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model
Majumder, P. K., Yeh, J. J., George, D. J., Febbo, P. G., Kum, J., Xue, Q., Bikoff, R., Ma, H., Kantoff, P. W., Golub, T. R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1232229100 · Cited by 285
Hutchinson, J., Jin, J., Cardiff, R. D., Woodgett, J. R., & Muller, W. J. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.6.2203-2212.2001 · Cited by 280
Akt Is a Direct Target of the Phosphatidylinositol 3-Kinase
Datta, K., Bellacosa, A., Chan, T. O., & Tsichlis, P. N. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.48.30835 · Cited by 279
Staal, S. P., Hartley, J. W., & Rowe, W. P. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.7.3065 · Cited by 276
High-avidity human IgGκ monoclonal antibodies from a novel strain of minilocus transgenic mice
Fishwild, D. M., O'Donnell, S. L., Bengoechea, T., Hudson, D. V., Harding, F., Bernhard, S. L., Jones, D., Kay, R. M., Higgins, K. M., Schramm, S. R., et al. (1996) · Nature Biotechnology · doi:10.1038/nbt0796-845 · Cited by 266
SHAW, M., COHEN, P., & ALESSI, D. R. (1998) · Biochemical Journal · doi:10.1042/bj3360241 · Cited by 261
Antibody humanization: a case of the ‘Emperor’s new clothes’?
Clark, M. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01680-7 · Cited by 258
The Akt Pathway: Molecular Targets for Anti-Cancer Drug Development
Mitsiades, C., Mitsiades, N., & Koutsilieris, M. (2004) · Current Cancer Drug Targets · doi:10.2174/1568009043333032 · Cited by 253
Jiang, K., Coppola, D., Crespo, N. C., Nicosia, S. V., Hamilton, A. D., Sebti, S. M., & Cheng, J. Q. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.1.139-148.2000 · Cited by 240
Self-citationSmall-molecule cyclin-dependent kinase modulators
Senderowicz, A. M. (2003) · Oncogene · doi:10.1038/sj.onc.1206954 · Cited by 236
Novel Small Molecule Inhibitors of 3-Phosphoinositide-dependent Kinase-1
Feldman, R. I., Wu, J. M., Polokoff, M. A., Kochanny, M. J., Dinter, H., Zhu, D., Biroc, S. L., Alicke, B., Bryant, J., Yuan, S., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501367200 · Cited by 228
Human cancer, PTEN and the PI-3 kinase pathway
Parsons, R. (2004) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2003.12.021 · Cited by 224
AKT crystal structure and AKT-specific inhibitors
Kumar, C. C., & Madison, V. (2005) · Oncogene · doi:10.1038/sj.onc.1209087 · Cited by 206
Structural Basis for Chk1 Inhibition by UCN-01
Zhao, B., Bower, M. J., McDevitt, P. J., Zhao, H., Davis, S. T., Johanson, K. O., Green, S. M., Concha, N. O., & Zhou, B.-B. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201233200 · Cited by 206
Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine)
Sato, S., Fujita, N., & Tsuruo, T. (2002) · Oncogene · doi:10.1038/sj.onc.1205225 · Cited by 206
AKT/PKB signaling mechanisms in cancer and chemoresistance
Kim, D. (2005) · Frontiers in Bioscience · doi:10.2741/1592 · Cited by 204
Akt Mediates Ras Downregulation of RhoB, a Suppressor of Transformation, Invasion, and Metastasis
Jiang, K., Sun, J., Cheng, J., Djeu, J. Y., Wei, S., & Sebti, S. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.12.5565-5576.2004 · Cited by 182
Self-citationFrequent activation of AKT2 kinase in human pancreatic carcinomas
Altomare, D. A., Tanno, S., De Rienzo, A., Klein‐Szanto, A. J., Tanno, S., Skele, K. L., Hoffman, J. P., & Testa, J. R. (2002) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10287 · Cited by 174
DeFeo-Jones, D., Barnett, S. F., Fu, S., Hancock, P. J., Haskell, K. M., Leander, K. R., McAvoy, E., Robinson, R. G., Duggan, M. E., Lindsley, C. W., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.271.4.2 · Cited by 173
Self-citationAdini, I., Rabinovitz, I., Sun, J. F., Prendergast, G. C., & Benjamin, L. E. (2003) · Genes & Development · doi:10.1101/gad.1134603 · Cited by 172
Searching for the elusive targets of farnesyltransferase inhibitors
Sebti, S. M., & Der, C. J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1234 · Cited by 169
Kawakami, Y., Nishimoto, H., Kitaura, J., Maeda-Yamamoto, M., Kato, R. M., Littman, D. R., Rawlings, D. J., & Kawakami, T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408797200 · Cited by 166
Van Ummersen, L., Binger, K., Volkman, J., Marnocha, R., Tutsch, K., Kolesar, J., Arzoomanian, R., Alberti, D., & Wilding, G. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0406 · Cited by 158
Cheng, J. Q., Jiang, X., Fraser, M. E., Li, M., Dan, H. C., Sun, M., & Tsang, B. K. (2002) · Drug Resistance Updates · doi:10.1016/s1368-7646(02)00003-1 · Cited by 149
Self-citationCheng, J. Q., Altomare, D. A., Klein, M. A., Lee, W.-C., Kruh, G. D., Lissy, N. A., & Testa, J. R. (1997) · Oncogene · doi:10.1038/sj.onc.1201121 · Cited by 148
Self-citationBarnett, S., Bilodeau, M. T., & Lindsley, C. W. (2005) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026053507714 · Cited by 146
Self-citationDiscovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors
Zhao, Z., Leister, W., Robinson, R., Barnett, S. F., Defeo-Jones, D., Jones, R. E., Hartman, G. D., Huff, J. R., Huber, H. E., Duggan, M. E., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.12.062 · Cited by 146
Self-citationAsnaghi, L., Calastretti, A., Bevilacqua, A., Dagnano, I., Gatti, G., Canti, G., Delia, D., Capaccioli, S., & Nicolin, A. (2004) · Oncogene · doi:10.1038/sj.onc.1207698 · Cited by 140
Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects
Prendergast, G. C. (2000) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)00072-1 · Cited by 134
Komander, D., Kular, G. S., Jennifer, B. A. I. N., Elliott, M., Alessi, D. R., & van Aalten, D. M. F. (2003) · Biochemical Journal · doi:10.1042/bj20031119 · Cited by 126
Castillo, S. S., Brognard, J., Petukhov, P. A., Zhang, C., Tsurutani, J., Granville, C. A., Li, M., Jung, M., West, K. A., Gills, J. G., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1530 · Cited by 124
Partovian, C., & Simons, M. (2004) · Cellular Signalling · doi:10.1016/j.cellsig.2004.01.008 · Cited by 123
Oncogenic transformation induced by membrane-targeted Akt2 and Akt3
Mende, I., Malstrom, S. E., Tsichlis, P. N., Vogt, P. K., & Aoki, M. (2001) · Oncogene · doi:10.1038/sj.onc.1204486 · Cited by 105
Inhibition of Akt Kinase Activity by a Peptide Spanning the βA Strand of the Proto-oncogene TCL1
Hiromura, M., Okada, F., Obata, T., Auguin, D., Shibata, T., Roumestand, C., & Noguchi, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403775200 · Cited by 103
Strategies to target HER2/neu overexpression for cancer therapy
Chen, J., Lan, K., & Hung, M. (2003) · Drug Resistance Updates · doi:10.1016/s1368-7646(03)00040-2 · Cited by 102
Dan, H. C., Jiang, K., Coppola, D., Hamilton, A. D., Nicosia, S. V., Sebti, S. M., & Cheng, J. Q. (2004) · Oncogene · doi:10.1038/sj.onc.1207171 · Cited by 93
Self-citationMalstrom, S. E., Tili, E., Kappes, D. J., Ceci, J. D., & Tsichlis, P. N. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231467698 · Cited by 93
Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents
Rao, R. D., Buckner, J. C., & Sarkaria, J. N. (2004) · Current Cancer Drug Targets · doi:10.2174/1568009043332718 · Cited by 89
Senderowicz, A. M. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0624-x · Cited by 84
Phosphoinositide 3-Kinases as Targets for Therapeutic Intervention
Wetzker, R., & Rommel, C. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043384402 · Cited by 79
Meric‐Bernstam, F. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.10.013 · Cited by 76
Pseudosubstrate Peptides Inhibit Akt and Induce Cell Growth Inhibition
Luo, Y., Smith, R. A., Guan, R., Liu, X., Klinghofer, V., Shen, J., Hutchins, C. W., Richardson, P., Holzman, T., Rosenberg, S. H., et al. (2004) · Biochemistry · doi:10.1021/bi034515p · Cited by 62
Breitenlechner, C. B., Friebe, W.-G., Brunet, E., Werner, G., Graul, K., Thomas, U., Künkele, K., Schäfer, W., Gaßel, M., Bossemeyer, D., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049701n · Cited by 60
Phosphoinositide 3‐kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells
Tabellini, G., Cappellini, A., Tazzari, P. L., Falà, F., Billi, A. M., Manzoli, L., Cocco, L., & Martelli, A. M. (2004) · Journal of Cellular Physiology · doi:10.1002/jcp.20153 · Cited by 60
Feun, L. G., Blessing, J. A., Barrett, R. J., & Hanjani, P. (1993) · American Journal of Clinical Oncology · doi:10.1097/00000421-199312000-00010 · Cited by 59
Proapoptotic Activity of Cell-Permeable Anti-Akt Single-Chain Antibodies
Shin, I., Edl, J., Biswas, S., Lin, P. C., Mernaugh, R. L., & Arteaga, C. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2898 · Cited by 55
Auguin, D., Barthe, P., Royer, C. A., Stern, M., Noguchi, M., Arold, S. T., & Roumestand, C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400364200 · Cited by 52
Liu, A., & Prendergast, G. C. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)02003-2 · Cited by 47
PI 3-kinase inhibition: a therapeutic target for respiratory disease
Finan, P. M., & Thomas, M. (2004) · Biochemical Society Transactions · doi:10.1042/bst0320378 · Cited by 45
Breast conservation in breast cancer: surgical and adjuvant considerations
Meric‐Bernstam, F. (2004) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/00001703-200402000-00007 · Cited by 12
Cited by
Perturbations of the AKT signaling pathway in human cancer
Altomare, D. A., & Testa, J. R. (2005) · Oncogene · doi:10.1038/sj.onc.1209085 · Cited by 1,329
FOXO transcription factors at the interface between longevity and tumor suppression
Greer, E. L., & Brunet, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209086 · Cited by 1,310
Akt signalling in health and disease
Hers, I., Vincent, E. E., & Tavaré, J. M. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.05.004 · Cited by 1,239
Larue, L., & Bellacosa, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209091 · Cited by 1,228
Current development of mTOR inhibitors as anticancer agents
Faivre, S., Kroemer, G., & Raymond, E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2062 · Cited by 1,000
Metadata
- Authors
- Cheng, J. Q., Lindsley, C. W., Cheng, G. Z., Yang, H., & Nicosia, S. V.
- Venue
- Oncogene
- Published
- 2005-11-14
- Volume
- 24
- Issue
- 50
- Pages
- 7482-7492
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2075556692
- Cited by
- 498
- References
- 109
- FWCI
- 13.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.